Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Five-year research partnership targets breast cancer vaccine


News release, March 21 2017

Five-year research partnership targets breast cancer vaccine

Imagine if no one died from breast cancer…if we stopped it in its tracks, so it couldn’t spread and kill.

That’s the aim of a new five-year research partnership between Breast Cancer Foundation NZ and Ferrier Research Institute at Victoria University in Wellington.

The first project in the new BCFNZ Ferrier Breast Cancer Research Programme will see Ferrier’s team of world-leading carbohydrate chemists, headed by Professor Richard Furneaux, pouring its considerable skills into developing a “therapeutic vaccine” for breast cancer.

Unlike regular vaccines given to healthy people to prevent disease developing, a therapeutic vaccine will stimulate a patient’s own immune system to attack and destroy breast cancer cells. Excitingly, the first use of such a vaccine is likely to be in patients with currently incurable cancer that has spread beyond the breast, or in those whose tumours are resistant to existing treatments and likely to spread. (Almost all breast cancer deaths are the result of the cancer spreading; whereas cancer that’s confined to the breast can be treated successfully).

Breast Cancer Foundation NZ has pledged an initial $500,000 to the BCFNZ Ferrier Breast Cancer Research Programme, which will focus on bringing new drugs – starting with a therapeutic vaccine – to the clinical trial stage. The partnership will run for at least five years.

“We went looking for a research partner who would give us the best shot of moving toward our vision of zero deaths from breast cancer,” said Evangelia Henderson, chief executive at BCFNZ. “We were blown away by the calibre of the Ferrier team, the work they’d already done in the exciting field of immunotherapy and vaccines, and the strength of their international partnerships. It was a no-brainer for us.”

The Breast Cancer Foundation will, as usual, be relying on the generosity of its donors and corporate supporters to fund this new research partnership, and Evangelia Henderson is hopeful that the Foundation’s Pink Ribbon Breakfast fundraising campaign, held in May, will be a big boost to its funds available for research. “This is a great chance to get in on the ground floor of new drug development right here in New Zealand. There are no guarantees in research, and it’s always a long haul, but we feel that Ferrier is ideally placed to turn the vaccine vision into reality. We’ll be looking to raise funds to ensure their work is well resourced to go full speed ahead.”

Ferrier’s successful immunotherapy treatment platform has already led to the establishment of biotechnology company Avalia Immunotherapies, which aims to commercialise vaccine technology to help New Zealanders. Avalia’s CEO is Dr Shivali Gulab, a former NZBIO Young Bioscientist of the Year who is based in New York and driving the progress of Ferrier’s vaccine technology towards human clinical trials. Ferrier Research Institute has had a 20-year working relationship with the Albert Einstein College of Medicine in New York, which has resulted in successful drug trials, including current trials in leukaemia and lymphoma.

“Our vision is zero deaths from breast cancer. That can’t happen without significant investment in game-changing areas, and right now vaccines are top of the list,” said Evangelia Henderson. “We’re so grateful to all our supporters who helped make this programme possible, and who will be as excited as we are about the fantastic work at Ferrier.”

Ferrier Institute director Professor Richard Furneaux says the technology for synthetic cancer vaccines is almost there. “We just need to get it to the next level of testing—human clinical trials.”

Professor Gavin Painter, who leads the chemistry team at Ferrier, says the support of BCFNZ is crucial. “Getting a new therapy to human clinical trials requires significant investment, and an intensive campaign of chemistry, biology and regulatory compliance.


ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Bus-iness: Transdev To Acquire More Auckland And Wellington Operations

Transdev Australasia today announced that it has agreed terms to acquire two bus operations in Auckland and Wellington, reaching agreement with Souter Investments to purchase Howick and Eastern Buses and Mana Coach Services. More>>

ALSO:

Māui And Hector’s Dolphins: WWF/Industry Counter Offer On Threat Management Plan

Forest & Bird says WWF-NZ's plan for protecting Māui dolphins is based on testing unproven methods on a species that is almost extinct, and is urging the Government to reject the proposal. More>>

ALSO:

Industry Report: Growing Interactive Sector Wants Screen Grants

Introducing a coordinated plan that invests in emerging talent and allows interactive media to access existing screen industry programmes would create hundreds of hi-tech and creative industry jobs. More>>

ALSO:

Ground Rules: Government Moves To Protect Best Growing Land

“Continuing to grow food in the volumes and quality we have come to expect depends on the availability of land and the quality of the soil. Once productive land is built on, we can’t use it for food production, which is why we need to act now.” More>>

ALSO: